Jyoti S. Mayadev, MD, Discusses Rationale for Assessing Durvalumab/CRT Vs Placebo/CRT in High-Risk Locally Advanced Cervical Cancer

Video

The randomized, placebo-controlled, double-blind phase 3 CALLA trial assessed the combination of durvalumab and chemoradiotherapy vs placebo and chemoradiotherapy.

At the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, Jyoti S. Mayadev, MD, a radiation oncologist and professor of radiation medicine and applied sciences at the University of California, San Diego School of Medicine, spoke with CancerNetwork® about the rationale of the phase 3 CALLA trial (NCT03830866) assessing durvalumab (Infinzi) in combination with chemoradiotherapy (CRT) compared with placebo and CRT in patients with high-risk locally advanced cervical cancer.

Mayadev also explained how the trial could potentially fulfil unmet needs in a population of patients with recurrence rates that are in need of improvement.

Transcript:

Locally advanced cervical cancer continues to represent an unmet medical need, especially in patients who have node-positive and periodic node–positive disease for which recurrence rates have been historically more than 50%. As a community of radiation oncologists who specialize in cervical cancer we really want to improve upon outcomes for these patients with cervical cancer. At the same time, we know that the majority of cervical cancer is caused by human papillomavirus; we know that it's immunogenic. We've done a series of phase 1 trials through the National Cancer Institute [NCI] that have shown us that combining immunotherapy with chemoradiation, whether it's concurrently or sequentially, is safe and tolerable and has shown really nice signals of efficacy. With AstraZeneca as our study sponsor, we were able to move immunotherapy and chemoradiation in the up-front definitive setting for patients with high-risk, stage III/IV node-positive locally advanced cervical cancer.

The goal of the CALLA trial was to improve outcomes for patients with this disease. It was a randomized, placebo-controlled double-blinded phase 3 trial looking at durvalumab concurrently and sequentially with chemoradiotherapy vs placebo/chemoradiation.

Reference

Mayadev JS, Rong, Y, Toita T, et al. Durvalumab in combination with chemoradiotherapy (CRT) in locally advanced cervical cancer (LACC): radiotherapy (RT) delivery and subgroup analyses from CALLA. Presented at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting; October 23-26, 2022; San Antonio, TX; LBA 03. Accessed October 27, 2022.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content